RxDoctor Payments Data

Elena Gurova, MD

Internal Medicine · Cleburne, TXNPI 1023002144

Payments from drug & device makers

$999in general payments, 2019–2025

Across 91 payments — averaging $10.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$264
  • Novo Nordisk$242
  • AbbVie$211
  • Lilly USA, LLC$89
  • Merck$62
  • Takeda Pharmaceuticals U.S.A., Inc.$20
  • plus $111 from 7 others

What the payments were for

  • Food & beverage$98098%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$999 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,928
Medicare patients
167
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$119,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter123$87,540
OzempicSemaglutide68$81,608
EliquisApixaban70$68,736
MounjaroTirzepatide41$44,173
MyrbetriqMirabegron55$40,657
Spiriva RespimatTiotropium Bromide30$22,068
JanuviaSitagliptin Phosphate17$21,569
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$20,722
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$16,799
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$11,780
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,292
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$10,022
Albuterol Sulfate HfaAlbuterol Sulfate384$9,415
Gabapentin449$9,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$264$141,738146 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$16$101,186148 claims
Novo NordiskOzempic$242$81,60868 claims
PfizerEliquis$15$68,73670 claims
Lilly USA, LLCMounjaro, Humalog, Humulin 70-30$89$49,58568 claims
MerckJanuvia$62$21,56917 claims
AstraZenecaBreztri Aerosphere, Symbicort$13$14,58630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →